



Company Overview

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases because of the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

May 3 2021, 9:00 AM EDT

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

Apr 27 2021, 8:30 AM EDT

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Apr 21 2021, 9:00 AM EDT

Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	86.5m
Last Price	\$1.40
52-Week	\$0.86 - \$4.25

05/06/2021 04:00 PM EDT

Investor Relations

Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com

Management Team

Joseph J. Sarret, M.D., J.D.

Chief Executive Officer and Director

Kenneth C. Cundy, Ph.D.

Chief Scientific Officer

Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

CohBar, Inc.

1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.